Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Not yet recruiting 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Renal Cell 2Kidney Neoplasms 1

Interventions

Specimen Handling 7Nivolumab 6pembrolizumab 4lenvatinib 3cabozantinib 3Axitinib 3vorolanib 2fludarabine 2anlotinib 2Sunitinib 2Nephrectomy 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Cyclophosphamide 2Biopsy 2toripalimab 1tivozanib 1sintilimab 1pazopanib 1fludarabine phosphate 1enzalutamide 1cemiplimab 1bemarituzumab 1belzutifan 1balstilimab 1atezolizumab 1abiraterone 1Zoledronic Acid 1Saline Solution 1Rubidium-82 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma, Renal Cell × vorolanib × Clear all
NCT06577961 2024-08-29

Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1/2 Not yet recruiting
37 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT06523049 2024-07-26

Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy

West China Hospital

Phase 2 Not yet recruiting
67 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡